PTC Therapeutics (PTCT) shares soared 9.7% in the last trading session to close at $36.52. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.3% loss over the past four weeks. This rise in share price is attributable to the company’s progress with its pipeline development. Last week, management reported encouraging interim data from the mid-stage PIVOT-HD study evaluating PTC518, its investigational treatment for Huntington's dis ...

WARREN, N.J., June 21, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 17, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,380 shares of its common stock and 6,260 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to nine new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The ...

- FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held June 20th at 8:00 am EDT - WARREN, N.J., June 20, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients. At Month 12, PTC518 treatment resulted in dose-dependent lowering of mutant huntingtin (mHTT) protein in the blood and cerebrospinal fluid (CSF) in the interim cohort of patients. In add ...

PTC Therapeutics, Inc. (PTCT) announced that the European Commission (EC) has decided against adopting the Committee for Medicinal Products for Human Use’s (CHMP) negative opinion of January 2024 on the annual renewal of the conditional marketing authorization of Translarna (ataluren). Translarna is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. Following the decision, the EC has returned the opinion t ...

- PDUFA target action date of November 13, 2024 - WARREN, N.J., May 14, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024. "We are excited to be one step closer to bringing an approved therapy to patients with ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Jane Hanlon - Associate Director of Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Kylie O’Keefe - Chief Commercial Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jefferies Samantha Corwin - William Blair Joseph Thome - TD Cowen Gena Wang - Bar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35969 PTC Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 04-3416587 (Stat ...

Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results – Strong revenue performance across product portfolio – – Submitted MAA for sepiapterin and BLA for Upstaza – – On target to achieve remaining 2024 clinical and regulatory milestones, including global submissions for sepiapterin – WARREN, N.J., April 25, 2024 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2024. “We ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Ron Aldridge - Senior Director, IR Matthew Klein - CEO Eric Pauwels - CBO Kylie O'Keefe - CCO Pierre Gravier - CFO Conference Call Participants Brooke Schuster - William Blair Rick Miller - Cantor Fitzgerald Eric Joseph - JPMorgan Jeff Hung - Morgan Stanley Brian Abrahams - RBC Capital Markets Peyton Bohnsack - TD Cowen David Lebowitz - Citi Gena Wang - Barclays Paul Choi - Goldman Sachs J ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35969 PTC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 04-3416587 (State or other jurisdiction of incorporati ...